VivoSeq
Oncology

Peripheral T-Cell Lymphoma

6

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Peripheral T-Cell Lymphoma is an early-stage landscape with 6 programs across 5 companies. The most active players are Regeneron, Incyte, Chipscreen Biosciences, Ltd..

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 1Incyte logo

Incyte

1 program

Phase 1C

Chipscreen Biosciences, Ltd.

1 program

Phase 2G

Great Novel Therapeutics Biotech & Medicals Corporation

0 programs

PreclinicalK

Kura Oncology, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 89% of 9 pipeline programs.

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Available1 · 25%

Clinical Trials

Trial Activity

A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Recruiting·GGreat Novel Therapeutics Biotech & Medicals Corporation·Phase 2·NCT05833724·33 enrolled
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT03922724·330 enrolled
MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Recruiting·MMayo Clinic·Phase 1·NCT06508463·21 enrolled
Expanded Access to Tipifarnib
Available·KKura Oncology, Inc.·N/A·NCT04809233

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)